Congratulations Dr Lucy Fox, presenting the results of IBMDx - genomics studies in inherited bone marrow failure syndromes - today in the late-breaking abstract session at #ASH25

Dr. Lucy Fox for outstanding talk at #LBA #ASH25 Whole Genome Sequencing upfront in large cohort of adult & pediatric pts with suspected IBMFS found high diagnostic rate (37.1%) - cost is ~8100 $ but expected to 📉 - impact on patient counselling & therapy - new discoveries

Scientific workshop on Translational Diagnostics in MRD - NGS, ctDNA and Beyond! TODAY - OCCC W311ABCD at 3pm. Full spectrum from latest lab tech through novel MRD adapted clinical trials in lymphoid and myeloid malignancy. See you there! #ASH25 #HemeSky #hematology @ash.hematology.org

Two patients with refractory myeloma who had excellent antitumor responses to cilta-cel CAR T-cell therapy later had T-cell lymphomas that contained the lentivirus construct used to generate the CAR T-cell product. Brief Report on the CARTITUDE-4 trial: nej.md/4gA6G27 #MedSky #Hematology

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma | NEJM

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cil...

nej.md

A recent case report from MSKCC published in the NEJM describes the development of a CD4+ T-cell lymphoma in a patient with multiple myeloma following B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy. www.nejm.org/doi/full/10....

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...

nejm.org

A woman with multiply relapsed multiple myeloma had complete remission with cilta-cel, but a low-grade T-cell lymphoma soon developed in the GI tract that contained an insertion of the CAR construct disrupting expression of p53. Read the Brief Report: nej.md/40Yq3gO #MedSky #Oncology

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...

nej.md

Attempt at putting what we know about #BTK resistance mutations into one figure.. Beware inducing cross-resistant L528Wmuts pre ncBTKi. #hemesky #hematology #lymsm #hemepath #NGS pubmed.ncbi.nlm.nih.gov/39808800/

Make sure you are testing for UBTF-TDs in paed MDS/AML (and adult MDS/AML!). Morphological/immunophenotypic clues = dysplasia in paed AML, CD34/CD117 dim Molecular clues = FLT3mut/WT1mut Menin inhibition as potential therapeutic modality. #hemesky #hemepath journals.lww.com/ajsp/fulltex...

Pediatric Myeloid Neoplasms With UBTF Tandem Duplications:... : The American Journal of Surgical Pathology

e of AML. To further our understanding of myeloid neoplasms with UBTF-TD, we analyzed clinical, morphologic, and immunophenotypic characteristics of 27 pediatric patients with UBTF-TD-positive myeloid...

journals.lww.com

CD274 3’UTR deletion and genomically hardwired #PDL1 over expression as an adaptive survival mechanism to #atezolizumab.. ?specific mechanism to targeting the tumour side of the immune synapse #hemesky #hemepath doi.org/10.1080/1042...

Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma

Published in Leukemia & Lymphoma (Ahead of Print, 2024)

doi.org

What a joy it is to hear our very own Sant-Ryan Pasricha presenting Best of #ASH24. Who else could personalise this so much and use a picture of the hallowed ground of the @MCG (Melbourne Cricket Ground) to such good effect? Go Santa!

Therapy related myeloid neoplasm post CART in DLBCL arises from TP53 clones identifiable preCART… but high baseline incidence of TP53/PPM1D CH preCART.. so the challenge is identifying those with clones that will progress - Zhi Han Yeoh from @petermaccc.bsky.social. #ASH24 #hemepath #hemesky #lymsm

Very interesting R-CHOP+X session (or Pola-R-CHP+X..) in DLBCL. 3/6 presentations in the session with data presented on ctDNA MRD!.. including the COALITION study (Adrian Minson/ @drmikedickinson.bsky.social. CtDNA helpful in resolving nature of EOT PET abnormalities #ASH24 #lymsm #hemesky #hemepath

Critical RW data, especially data re: better PFS for pola for non-GC in the post-CAR setting. Huge congratulations to Drs. Cliff and Russler-Germain for this tour de force, and for inviting us at @CULymphoma @CUHematology (and @JessicaAllenMD) to participate. #ASH24 #lymsm

Zoe McQuilten from Monash 🇦🇺presenting the final results of the Diaamond-AVA-first looking at hATG, CSA, and avatromboag. Similar results to eltrombopag seen. #ASH24 @ash-hematology.bsky.social

Dr. Jacoby from Washington University on intervening in AML based on mut clearance at 2.5% VAF across exome level in a variant agnostic way. Great to see this “fingerprint” MRD approach being used in trials.. lots of analogies to current lymphoma ctDNA space #hemepath #hemesky #leusm #lymsm #ASH24

Exciting to see the first results from the INTERCEPT platform study (PI Andrew Wei) expertly presented by Dr. Sun Loo from @petermaccc.bsky.social at #ASH24. Intervening with a molecularly rational approach at early #MRD relapse is feasible in AML and the results with revumenib are encouraging.

Dr. Ing Soo Tiong from @petermaccc.bsky.social presenting his excellent work at #ASH24 on how the remission clonal haematopoietic landscape is shaped by venetoclax in pts with AML. TP53 and BAX microclones! With a bit more sensitive sequencing tech we will find the nanoclones… #hemepath #hemesky

A great (in-person!) meeting of the MM-VCEP #ClinGen group today at #ASH24. Lots of exciting projects and milestones for the group on the horizon including making rules for new genes (SAMD9/SAMD9L/TERT/TERC..) as well as progress on our DDX41 curation rules. Stay tuned..

Loss of function TET2 germline variants.. potentially a lot more common than previously thought.. Well done to Sean Harrop presenting our work on this emerging immune dysregulatory syndrome in the germline BMF workshop at #ASH24 #hemepath #hemesky

Blood experts unite Hmmm.. so what do we need now? I know, pickleball.. #ASHaiku #ASH24

Looking forward to the Germline Predisposition FSW at #ASH24… (check out summary at link below!). For those attending - make sure you stay to hear Sean Harrop present our work on germline #TET2 variants and an emerging novel syndrome.. #hemesky #hemepath #hematology youtu.be/UEKszF06k2Y

ASH 2024 Friday Scientific Workshop on Germline Predisposition to Hematologic Malignancies and BMF

YouTube video by Marcin W

youtu.be

NGS variants prior to CAR #ASH24: - 173 pts, 63% axi-cel - 43% had CH prior to CAR: 54% DNMT3A, 26% TP53 - 6% developed MN: 3-yr cumulative incidence of 11% with death from LBCL as competing risk - median time CAR to MN 25 mos - CH➡️late thrombocytopenia after CAR #lymsm #bmtsm

We recently joined forces with the University of Melbourne to create the Collaborative Centre for Genomic Cancer Medicine. It's Director Prof Sean Grimmond and A/Prof David Westerman joined ABC Melbourne to talk about the new centre's mission and future of #genomicmedicine. A fascinating listen!

Why are scientists so excited about genomics? - ABC listen

Genomics explores the building blocks of human DNA, in the hopes of uncovering patterns that can lead to lifesaving medical discoveries.

abc.net.au